PBYI Puma Biotechnology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PBYI

Price (delayed)

$3.9

Market cap

$185.53M

P/E Ratio

55.71

Dividend/share

N/A

EPS

$0.07

Enterprise value

$215.95M

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights ...

Highlights
Puma Biotechnology's equity has surged by 75% YoY and by 27% QoQ
The revenue has grown by 5% YoY
PBYI's EPS has dropped by 68% year-on-year
The net income has plunged by 62% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.pumabiotechnology.com
Peers: ARRY PFE

Key stats

What are the main financial stats of PBYI
Market
Shares outstanding
47.57M
Market cap
$185.53M
Enterprise value
$215.95M
Valuations
Price to earnings (P/E)
55.71
Price to book (P/B)
4.78
Price to sales (P/S)
0.81
EV/EBIT
12.12
EV/EBITDA
7.54
EV/Sales
0.94
Earnings
Revenue
$229.13M
EBIT
$17.81M
EBITDA
$28.65M
Free cash flow
$24.14M
Per share
EPS
$0.07
Free cash flow per share
$0.51
Book value per share
$0.82
Revenue per share
$4.82
TBVPS
$2.95
Balance sheet
Total assets
$203.61M
Total liabilities
$164.86M
Debt
$112.22M
Equity
$38.74M
Working capital
$57.99M
Liquidity
Debt to equity
2.9
Current ratio
1.86
Quick ratio
1.69
Net debt/EBITDA
1.06
Margins
EBITDA margin
12.5%
Gross margin
75.9%
Net margin
1.6%
Operating margin
12.2%
Efficiency
Return on assets
1.8%
Return on equity
12.8%
Return on invested capital
15%
Return on capital employed
13.1%
Return on sales
7.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PBYI stock price

How has the Puma Biotechnology stock price performed over time
Intraday
0.52%
1 week
-5.8%
1 month
55.38%
1 year
-13.72%
YTD
-7.8%
QTD
48.29%

Financial performance

How have Puma Biotechnology's revenue and profit performed over time
Revenue
$229.13M
Gross profit
$173.94M
Operating income
$27.86M
Net income
$3.72M
Gross margin
75.9%
Net margin
1.6%
Puma Biotechnology's net margin has shrunk by 64% YoY
The net income has plunged by 62% YoY
The operating income has grown by 36% YoY and by 29% from the previous quarter
The operating margin has grown by 30% from the previous quarter and by 30% YoY

Growth

What is Puma Biotechnology's growth rate over time

Valuation

What is Puma Biotechnology stock price valuation
P/E
55.71
P/B
4.78
P/S
0.81
EV/EBIT
12.12
EV/EBITDA
7.54
EV/Sales
0.94
PBYI's EPS has dropped by 68% year-on-year
Puma Biotechnology's equity has surged by 75% YoY and by 27% QoQ
PBYI's P/B is 71% lower than its 5-year quarterly average of 16.5 and 18% lower than its last 4 quarters average of 5.8
PBYI's P/S is 42% below its 5-year quarterly average of 1.4 but 16% above its last 4 quarters average of 0.7
The revenue has grown by 5% YoY

Efficiency

How efficient is Puma Biotechnology business performance
Puma Biotechnology's ROE has plunged by 85% YoY
PBYI's ROIC has soared by 65% QoQ but it is down by 18% YoY
PBYI's return on sales has surged by 63% since the previous quarter but it is down by 20% year-on-year
The ROA has shrunk by 63% YoY

Dividends

What is PBYI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PBYI.

Financial health

How did Puma Biotechnology financials performed over time
The total assets is 23% more than the total liabilities
The company's current ratio fell by 9% YoY and by 6% QoQ
The total liabilities has contracted by 7% YoY and by 3.1% from the previous quarter
Puma Biotechnology's debt is 190% higher than its equity
Puma Biotechnology's equity has surged by 75% YoY and by 27% QoQ
Puma Biotechnology's debt to equity has decreased by 44% YoY and by 22% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.